ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - ProKidney Corp. is a late clinical-stage biotech company focused on developing a first-in-class cell therapy candidate for chronic kidney disease (CKD) [1][3] - The company was founded in 2015 after a decade of research and is pioneering treatments for CKD through innovations in cellular therapy [3] Product Information - ProKidney's lead product candidate, rilparencel (also known as REACT), is an autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies [3] - Rilparencel aims to preserve kidney function in diabetic patients at high risk of kidney failure and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA [3] Upcoming Events - ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 7:30 am PST [1][2] - The management team will also host one-on-one meetings throughout the event, and a live webcast of the presentation will be available on the company's website [2]